Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Eosinophilic Esophagitis

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Open‑label Phase 1b/2a findings are guiding a randomized Phase 2b now enrolling that is slated to deliver top‑line data in Q3 2026.

Eupraxia Selects 8 mg Dose After Strong EoE Signals, Expands Phase 2b Trial